Monday, December 8, 2014

Imprimis Pharmaceuticals Expands Proprietary Ophthalmic Formulations to Four Additional States

mprimis Pharmaceuticals announced it is expanding the availability of its dropless formulations to more than 3,000 ophthalmologists in four states: California, Nevada, Oregon, and Hawaii, according to a company news release. These states represent mroe than 290 ambulatory surgery centers where cataract and other ocular surgeries are performed, including California which has the most ASCs dedicated to ocular surgery in the country.
Imprimis currently provides two proprietary compounded antibiotic and steroid formulations available in single, injectable intraocular doses administered during ocular surgery. The first formulation contains triamcinolone acetonide and moxifloxacin hydrochloride (Tri-Moxi), and a second variation includes the added antibiotic vancomycin (Tri-Moxi-Vanc). These medications are available with a physician's prescription for individual patients and have been administered in over 40,000 ophthalmic procedures, primarily cataract surgeries.

No comments: